QuantLogix 5-Factor Engine Pins HRMY at 94/100 Composite

The Setup

On the July 4, 2026 Independence Day holiday session, the QuantLogix 5-factor engine completed its full scan across the signal universe and placed Harmony Biosciences Holdings ($HRMY) at the top of the conviction list with a composite score of 94/100 — the highest reading of the day. The broader signal environment is itself skewed bullish: 568 Strong Buy labels versus 91 Strong Sell labels produces a 6.2-to-1 bullish-to-bearish ratio. HRMY's 0% price change on the session is a data artifact of U.S. market closure, not a momentum signal. The pre-holiday last traded price was $37.26. The real test is the July 7 opening print — the first live tape available to validate what the engine is reading.

The Read

A 94/100 composite score is a near-ceiling reading, and understanding what produces it matters more than the number itself. The QuantLogix methodology is explicit: "Scores above 90 reflect near-ceiling agreement across momentum, fundamental trend, technical structure, sentiment/flow, and relative strength sub-factors." That is multi-factor confluence, not a single-variable spike. The Pod-Shop Model framework makes the relevance clear — a signal that draws on five uncorrelated sub-factors is structurally more durable than one driven by a single input, because five independent lines of evidence pointing the same direction is not coincidence.

Walking the Five Sub-Factors

Momentum. In a CNS specialty pharma name with HRMY's volatility profile, momentum sub-factors typically capture price rate-of-change relative to sector peers and broader market over multi-week windows. A near-ceiling read here suggests pre-holiday price action was building, not stalling.

Fundamental trend. HRMY is a commercial-stage pharmaceutical company with a single approved asset: Wakix (pitolisant), which carries FDA labeling as indicated "for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy." A single-product commercial book means the fundamental trend sub-factor is entirely a function of Wakix revenue trajectory. A high sub-factor score suggests the revenue trend visible in the most recent filings — Harmony describes itself as "a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with central nervous system disorders" — is trending favorably relative to expectations.

Technical structure. At $37.26, HRMY sits in small-to-mid cap specialty pharma territory, a segment characterized by higher beta and event-driven volatility. The technical structure sub-factor scoring near-ceiling implies constructive pattern formation at the pre-holiday close — likely above key moving averages and not in an extended distribution pattern.

Sentiment/flow. Flow proxies for a name in this cap range often capture options market positioning, short-interest trends, and institutional filing changes. A high score here is a meaningful signal given how thin the analyst coverage and institutional float can be in specialty pharma.

Relative strength. HRMY leads the day's conviction list by one point over second-ranked TGHL (93/100) and by a 5-point margin over third-ranked AURA (89/100). Within a 568-name Strong Buy universe, being the outright top-ranked name is the most direct measure of relative strength the engine can produce.

Position Sizing Context

The Position Sizing by Conviction × Liquidity framework applies directly here. HRMY's small-to-mid cap profile and single-product concentration mean that even high composite conviction should be translated into a position size that accounts for exit cost in a stress scenario. High conviction in an illiquid name does not mean large sizing — it means appropriately sized with a pre-committed invalidation level. The Anti-Index Mindset framework is also relevant: small-to-mid cap specialty pharma names are structurally underweighted by passive flows, which means the opportunity set exists precisely because broad index buyers are not competing for the same float.

The Action

• Watch HRMY's July 7 opening print — a gap up with above-average volume relative to its 20-day ADV would confirm the 94/100 composite is translating into real price discovery; a flat or gap-down open on elevated sell volume is an immediate signal-invalidation flag.
• Pull up the QuantLogix HRMY signal detail page to review the sub-factor breakdown — identify which of the five factors is the primary driver, since single-factor spikes are less durable than multi-factor confluences. A "Composite score 94/100, label: Strong Buy, price: $37.26" headline number is the starting point, not the conclusion.
• Set an invalidation level before the July 7 open: for a $37.26 last price in a small-to-mid cap pharma, a close below the most recent swing low or below the 20-day moving average would suggest the composite signal is not finding price confirmation and warrants exiting or reducing the position.
• Cross-reference HRMY's signal against the broader 568-name Strong Buy universe — if TGHL (93/100) and AURA (89/100) are in unrelated sectors, that argues for HRMY as an idiosyncratic pick; if they cluster in CNS/healthcare, a sector-level tailwind may be amplifying individual scores across the board.
• Monitor the Harmony Biosciences news feed heading into the July 7 open for any FDA communications, competitive filings, or Wakix reimbursement and formulary developments — the 5-factor engine scores quantitative inputs and cannot price a regulatory tail event that has not yet appeared in the data.

The Counter

Three counter-arguments deserve direct treatment. First, a 94/100 signal generated on a holiday session with 0% price change and no live breadth data is, by construction, a pre-holiday close setup — not a confirmed live-tape read. The July 7 open is the validation event, and a signal that does not find price-and-volume confirmation on the first post-holiday session should be treated with meaningfully reduced conviction. Second, and more structurally important: HRMY is a single-product company. A single FDA safety communication, label update, or competitive approval in the narcolepsy space — orexin agonists and alternative sodium oxybate formulations are in various pipeline stages — can invalidate any quantitative composite signal overnight. The 5-factor engine processes what has happened; it cannot price binary regulatory risk that has not yet arrived. The Distressed & Macro framework on asymmetric risk applies here in reverse — the downside on single-product pharma is not gradual mean reversion, it is gap-down binary. Size accordingly. Third, a 6.2-to-1 Strong Buy-to-Sell ratio across the full 568-name universe raises the question of regime-wide score inflation — whether the engine is in a high-sensitivity mode that lifts all boats. That is a legitimate model-risk concern. The answer is that HRMY's 94 is still the outright top rank among 568 bullish names, meaning it is the marginal leader even in a permissive environment. But readers should contextualize HRMY's current score against its own historical score distribution, not just the daily cross-section. A 94 that is unusual for HRMY historically carries more weight than a 94 that sits near its recent average.

Primary Sources

• HRMY Signal Detail — QuantLogix 5-Factor Engine — QuantLogix, July 4, 2026
• Wakix (pitolisant) FDA Prescribing Information — Harmony Biosciences / FDA
• Harmony Biosciences Holdings 10-K / Most Recent Annual Filing — SEC EDGAR / Harmony Biosciences
• QuantLogix Signal Engine Methodology — 5-Factor Composite Framework — QuantLogix internal documentation